Sue-Jean Lin - 12 Jun 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role: Director
Signature: /s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin
Issuer symbol: ARQT
Transactions as of: 12 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2025, 20:18:08 UTC
Previous filing: 18 Jun 2024
Next filing: 25 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
LIN SUE-JEAN	Director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE	/s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin	16 Jun 2025	0001867788

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARQT	Common Stock	Award	$0	+7,609	+40%	$0.000000	26,735	12 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARQT	Stock Option (right to buy)	Award	$0	+20,568		$0.000000	20,568	12 Jun 2025	Common Stock	20,568	$13.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 21, 2024, maintained by the Company.
F2	The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Content

Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 21, 2024, maintained by the Company.

The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney